<DOC>
	<DOCNO>NCT02754830</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability study drug , LY3303560 . Side effect laboratory result monitor . This study involve single dos LY3303560 administer intravenously ( IV ) , mean vein subcutaneously ( SC ) , mean skin . Screening require within 28 day start study healthy participant within 42 day start study AD participant . The study require 16 week participant 's time include 4 day clinical research unit ( CRU ) admission 10 follow-up appointment . This first time study drug give participant . This study research purpose , intend treat medical condition .</brief_summary>
	<brief_title>A Study LY3303560 Healthy Participants Participants With Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Overtly healthy male female nonchildbearing potential give consent reliable willing make available duration study willing follow study procedure AD participant must least 50 year age diagnostic criterion consistent either mild cognitive impairment due AD mildto moderate AD positive florbetapir positron emission tomography ( PET ) scan Have know allergy LY3303560 , related compound component formulation , history significant atopy Have increase risk seizure For AD participant , evidence macrohemorrhage great 4 microhemorrhage magnetic resonance imaging ( MRI )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>